

# Marc N Hirt

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9445353/marc-n-hirt-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25  
papers

1,269  
citations

14  
h-index

27  
g-index

27  
ext. papers

1,521  
ext. citations

6.7  
avg, IF

4.19  
L-index

#	Paper	IF	Citations
25	Cardiac tissue engineering: state of the art. <i>Circulation Research</i> , <b>2014</b> , 114, 354-67	15.7	303
24	Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2014</b> , 74, 151-61	5.8	234
23	Human Engineered Heart Tissue: Analysis of Contractile Force. <i>Stem Cell Reports</i> , <b>2016</b> , 7, 29-42	8	217
22	Increased afterload induces pathological cardiac hypertrophy: a new in vitro model. <i>Basic Research in Cardiology</i> , <b>2012</b> , 107, 307	11.8	111
21	Human iPSC-derived cardiomyocytes cultured in 3D engineered heart tissue show physiological upstroke velocity and sodium current density. <i>Scientific Reports</i> , <b>2017</b> , 7, 5464	4.9	99
20	Long Noncoding RNA-Enriched Vesicles Secreted by Hypoxic Cardiomyocytes Drive Cardiac Fibrosis. <i>Molecular Therapy - Nucleic Acids</i> , <b>2019</b> , 18, 363-374	10.7	44
19	Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2015</b> , 81, 1-9	5.8	38
18	Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy. <i>European Heart Journal</i> , <b>2020</b> , 41, 3462-3474	9.5	35
17	Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation. <i>Circulation</i> , <b>2016</b> , 134, 817-32	16.7	34
16	Pharmacological inhibition of DNA methylation attenuates pressure overload-induced cardiac hypertrophy in rats. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2018</b> , 120, 53-63	5.8	26
15	Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue. <i>PLoS ONE</i> , <b>2016</b> , 11, e0145937	3.7	25
14	General practitioners adherence to chronic heart failure guidelines regarding medication: the GP-HF study. <i>Clinical Research in Cardiology</i> , <b>2016</b> , 105, 441-50	6.1	23
13	DNA methylation in an engineered heart tissue model of cardiac hypertrophy: common signatures and effects of DNA methylation inhibitors. <i>Basic Research in Cardiology</i> , <b>2016</b> , 111, 9	11.8	19
12	Spontaneous Formation of Extensive Vessel-Like Structures in Murine Engineered Heart Tissue. <i>Tissue Engineering - Part A</i> , <b>2016</b> , 22, 326-35	3.9	16
11	A magnetics-based approach for fine-tuning afterload in engineered heart tissues. <i>ACS Biomaterials Science and Engineering</i> , <b>2019</b> , 5, 3663-3675	5.5	11
10	Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue. <i>Scientific Reports</i> , <b>2019</b> , 9, 18152	4.9	10
9	An Important Role for DNMT3A-Mediated DNA Methylation in Cardiomyocyte Metabolism and Contractility. <i>Circulation</i> , <b>2020</b> , 142, 1562-1578	16.7	9

8	Toward Second-Generation Cardiomyogenic and Anti-cardiofibrotic 1,4-Dihydropyridine-Class TGF $\beta$ Inhibitors. <i>ChemMedChem</i> , <b>2019</b> , 14, 810-822	3.7	5
7	Blockade of miR-140-3p prevents functional deterioration in afterload-enhanced engineered heart tissue. <i>Scientific Reports</i> , <b>2019</b> , 9, 11494	4.9	4
6	Effects of the Delta Opioid Receptor Agonist DADLE in a Novel Hypoxia-Reoxygenation Model on Human and Rat-Engineered Heart Tissue: A Pilot Study. <i>Biomolecules</i> , <b>2020</b> , 10,	5.9	3
5	S100A4 as a Target of the E3-Ligase Asb2 and Its Effect on Engineered Heart Tissue. <i>Frontiers in Physiology</i> , <b>2018</b> , 9, 1292	4.6	2
4	Assessment of Cardiotoxicity With Stem Cell-based Strategies. <i>Clinical Therapeutics</i> , <b>2020</b> , 42, 1892-1910	3.5	1
3	Recapitulation of dyssynchrony-associated contractile impairment in asymmetrically paced engineered heart tissue. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2021</b> , 163, 97-105	5.8	0
2	Hypertrophic signaling compensates for contractile and metabolic consequences of DNA methyltransferase 3A loss in human cardiomyocytes. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2021</b> , 154, 115-123	5.8	0
1	Piezo2 is not an indispensable mechanosensor in murine cardiomyocytes.. <i>Scientific Reports</i> , <b>2022</b> , 12, 8193	4.9	0